Evidence map›Paper›PMID 32631746›Full record

ArticleEuropean urology2021

Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

Simpa S Salami, Jeffrey J Tosoian, Srinivas Nallandhighal, Tonye A Jones, Scott Brockman, Fuad F Elkhoury, Selena Bazzi, Komal R Plouffe, Javed Siddiqui, Chia-Jen Liu and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Simpa S SalamiDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA. Electronic address: simpa@med.umich.edu.
Jeffrey J TosoianDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Srinivas NallandhighalDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA.
Tonye A JonesDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Scott BrockmanDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA.
Fuad F ElkhouryDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Selena BazziDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA.
Komal R PlouffeDepartment of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Javed SiddiquiMichigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Chia-Jen LiuMichigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Lakshmi P KunjuDepartment of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Todd M MorganDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Shyam NatarajanDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Philip S BoonstraDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Lauren SumidaDepartment of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Scott A TomlinsDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Aaron M UdagerUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Michigan Center for Translational Pathology, Michigan Medicine, Ann Arbor, MI, USA; Department of Pathology, Michigan Medicine, Ann Arbor, MI, USA.
Anthony E SiskDepartment of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Leonard S MarksDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Ganesh S PalapattuDepartment of Urology, Michigan Medicine, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; Department of Urology, Medical University of Vienna, Vienna, Austria.
Michigan Medicine · USUniversity of California, Los Angeles · USMichigan Center for Translational Pathology · USUniversity of Michigan–Ann Arbor · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the ProstateR01CA158627 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2011 to 2013
$1.4M
NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R01 CA158627NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

backgroundThe potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear.

objectiveTo interrogate the molecular and biological features of low-grade PCa serially over time. DESIGN, SETTING, AND

participantsNested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017.

interventionElectronic tracking and resampling of PCa using magnetic resonance imaging/ultrasound fusion biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ERG immunohistochemistry (IHC) and targeted DNA/RNA next-generation sequencing were performed on initial and repeat biopsies. Tumor clonality was assessed. Molecular data were compared between men who upgraded and those who did not upgrade to GG ≥ 2 cancer. RESULTS AND LIMITATIONS: Sixty-six men with median age 64 yr (interquartile range [IQR], 59-69) and prostate-specific antigen 4.9 ng/mL (IQR, 3.3-6.4) underwent repeat sampling of a tracked tumor focus (median interval, 11 mo; IQR, 6-13). IHC-based ERG fusion status was concordant at initial and repeat biopsies in 63 men (95% vs expected 50%, p <  0.001), and RNAseq-based fusion and isoform expression were concordant in nine of 13 (69%) ERG

conclusionsRepeat molecular assessment of low-grade tumors suggests that clonal progression could be one mechanism of upgrading. These data underscore the importance of serial tumor assessment in men pursuing AS of low-grade PCa. PATIENT SUMMARY: We performed targeted rebiopsy and molecular testing of low-grade tumors on active surveillance. Our findings highlight the importance of periodic biopsy as a component of monitoring for cancer upgrading during surveillance.

Indexed as

ProstateProstatic NeoplasmsCohort StudiesHumansImage-Guided BiopsyLongitudinal StudiesMaleMiddle AgedNeoplasm GradingCancer progressionGene fusionsImmunohistochemistryLow-grade cancerNext-generation sequencingProstate cancerTumor clonality

Identifiers

PMID32631746
PMCPMC7779657
OpenAlexW3039530565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.